Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Merit Medical reported revenue of $384.16 million for the quarter ended September 2025, reflecting a 13% increase year-over-year and surpassing the Zacks Consensus Estimate of $371.21 million by 3.49% [1] - The company's EPS for the quarter was $0.92, up from $0.86 in the same quarter last year, exceeding the consensus EPS estimate of $0.82 by 12.2% [1] Financial Performance - The stock has returned -0.8% over the past month, while the Zacks S&P 500 composite increased by 3.6%, with a Zacks Rank 2 (Buy) indicating potential outperformance in the near term [3] - Geographic sales showed strong performance, with International sales at $153.56 million (+15.2% YoY), APAC at $64.86 million (+7.4% YoY), and the United States at $230.6 million (+11.7% YoY) [4] - EMEA sales reached $71.53 million, representing a 22.3% increase year-over-year, while the Rest of World sales were $17.17 million (+18.5% YoY) [4] Segment Performance - Revenue from Cardiovascular-Peripheral Intervention was $144.78 million (+5% YoY), while Cardiovascular-Cardiac Intervention saw a significant increase to $116.68 million (+28.6% YoY) [4] - Endoscopy revenue was reported at $17.73 million (+4.4% YoY), and Cardiovascular-OEM revenue was $50.83 million (+17.2% YoY) [4] - Overall Cardiovascular revenue totaled $366.43 million, reflecting a 13.5% increase year-over-year, with Custom Procedural Solutions revenue at $54.14 million (+6.6% YoY) [4]